Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A prospective multicenter intra-individual comparison trial. First line atezolizumab + ...
The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression. Risk of peritoneal recurrence ...
The use of liver-specific contrast agents, such as gadoxetic acid, in magnetic resonance imaging (MRI) has revolutionized the detection and characterization of hepatic nodules. In the HBP ...